株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

直腸癌:パイプライン製品の分析

Rectal Cancer - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 229750
出版日 ページ情報 英文 202 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
直腸癌:パイプライン製品の分析 Rectal Cancer - Pipeline Review, H1 2020
出版日: 2020年02月28日 ページ情報: 英文 202 Pages
概要

直腸癌は、結腸(大腸と肛門とをつなげる部分)の下半部に生じる腫瘍です。直腸癌発症のリスク要因には、加齢や喫煙、結腸癌・直腸癌の家族歴、高脂肪食または動物源が主体の食事、ポリープ・大腸癌の家族歴などがあります。また、主に肝臓・肺といった組織に転移します。一般的な徴候・症状として、排便習慣の変化、下痢、便秘、便を完全に排出しきれていない感覚、血便、頻繁なガス痛・膨満感・けいれんといった腹部の不快感、原因不明の体重減少、慢性的な倦怠感・吐き気などが挙げられます。主な治療法には、外科手術や放射線治療、化学療法、およびこれらの複合療法などがあります。

当レポートでは、世界各国での直腸癌治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

直腸癌の概要

治療薬の開発

  • 直腸癌向けパイプライン製品:概要

各企業で開発中の直腸癌治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

直腸癌治療薬:開発中の製品の一覧(企業別)

直腸癌治療薬の開発に従事している企業

  • AbbVie Inc
  • Advaxis, Inc.
  • Cerulean Pharma, Inc.
  • Hanwha Chemical Corporation
  • Karyopharm Therapeutics, Inc.
  • Regeneron Pharmaceuticals Inc
  • Taiwan Liposome Company, Ltd.

直腸癌:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

直腸癌治療薬:開発が休止状態の製品

直腸癌関連製品の開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Rectal Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rectal Cancer - Pipeline by AbbVie Inc, H1 2020
  • Rectal Cancer - Pipeline by AD Pharmaceuticals Co Ltd, H1 2020
  • Rectal Cancer - Pipeline by Advaxis Inc, H1 2020
  • Rectal Cancer - Pipeline by Apexigen Inc, H1 2020
  • Rectal Cancer - Pipeline by AptaBio Therapeutics Inc, H1 2020
  • Rectal Cancer - Pipeline by AstraZeneca Plc, H1 2020
  • Rectal Cancer - Dormant Projects, H1 2020
  • Rectal Cancer - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Rectal Cancer, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC12013IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Pipeline Review, H1 2020, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 7, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

Introduction

  • Rectal Cancer - Overview
  • Rectal Cancer - Therapeutics Development
  • Rectal Cancer - Therapeutics Assessment
  • Rectal Cancer - Companies Involved in Therapeutics Development
  • Rectal Cancer - Drug Profiles
  • Rectal Cancer - Dormant Projects
  • Rectal Cancer - Discontinued Products
  • Rectal Cancer - Product Development Milestones
  • Appendix